CD40 and neoplasm: Here, we will focus on how targeting CD40, a TNF superfamily receptor expressed on a variety of immune cells, can be leveraged to improve cancer immunity in several vaccine-related settings, with the focus that most forms of vaccination will have limited therapeutic efficacy in the complex tumor microenvironment when the appropriate adjuvants are omitted from the vaccine regimen.